If you are unable to access any of our publications, please email Daniel Wetterskog to obtain a copy.
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Grist E, et al. Genome Medicine. 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
Orlando F, et al. NAR Cancer. 2022
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Attard G, et al. Lancet. 2022
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
Jayaram A, et al. Ann Oncol. 2021
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.
Conteduca V, et al. JCO Precision Oncology. 2020
Genome-wide plasma DNA methylation features of metastatic prostate cancer.
Wu A, et al. The Journal of Clinical Investigation. 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.
Jayaram A, et al. JCO Precision Oncology. 2019
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V, et al. Ann Oncol. 2017
Plasma AR and abiraterone-resistant prostate cancer.
Romanel A, et al. Sci Transl Med. 2015
Tumor clone dynamics in lethal prostate cancer.
Carreira S, et al. Sci Transl Med. 2014